Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia

The option requires an upfront payment, with further payments and tiered royalties conditional on exercise and completion of the acquisition.

Rhea-AI Summary

NovaBridge Biosciences (NASDAQ: NBP) subsidiary Visara secured an exclusive option from YOLO Immune to acquire worldwide rights to the YOL104 Program. Visara is majority-owned by NovaBridge. The agreement gives Visara the opportunity to develop and commercialize YOL104-2 for ocular surface squamous neoplasia (OSSN), which includes cancerous and precancerous growths on the eye’s surface. YOL104-2 is an investigational interferon alpha peptibody, a bioengineered protein therapy.

Visara will make an upfront payment for the option. If it exercises the option and completes the acquisition, YOLO would receive an exercise payment and become eligible for development, regulatory and commercial milestone payments, plus tiered royalties on net sales. Financial amounts were not disclosed. Visara views the agreement as an opportunity to evaluate an additional ophthalmology program while preserving capital-allocation flexibility.

2 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointVisara secured an exclusive option to acquire worldwide YOL104 Program rights from YOLO Immune.
• Minor point. Forward-looking: it has not happened yet and may not happen.Visara sees YOL104-2 as a potential ophthalmology pipeline addition for ocular surface squamous neoplasia.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.Visara will make an upfront payment to obtain the exclusive option.
• Minor pointWorldwide ownership remains conditional on option exercise and completion of the acquisition.
• Minor point. Forward-looking: it has not happened yet and may not happen.Completed acquisition would trigger an exercise payment and eligibility for milestones and tiered net-sales royalties.

Key Terms

peptibody, interferon alpha, tiered royalties

3 terms

peptibody medical

"YOL104-2 is a trivalent interferon alpha (IFN-α) peptibody"

A peptibody is a engineered biologic made by fusing a short functional peptide to the constant (Fc) region of an antibody, producing a single recombinant protein that combines the peptide's target-binding activity with the Fc domain's stability and pharmacokinetic properties. The Fc portion increases molecular size to slow renal clearance, allows interactions with Fc receptors and the neonatal Fc receptor (extending circulating half-life), and simplifies manufacturing compared with full monoclonal antibodies; unlike a full antibody, target recognition comes from the peptide sequence rather than complementary-determining regions on antibody variable domains.

interferon alpha medical

"YOL104-2 is a trivalent interferon alpha (IFN-α) peptibody"

Interferon alpha is a naturally occurring protein produced by the immune system that acts like an alarm, signaling cells to defend against viruses and abnormal growth. As a medication, it is used to treat certain viral infections and cancers; investors watch its clinical trial results, regulatory approvals, production capacity, and patent status because those factors determine commercial value, sales potential, and risk similar to how a product launch affects a company's prospects.

tiered royalties financial

"as well as tiered royalties on net sales"

Tiered royalties are a payment structure where the percentage of earnings paid as royalties changes based on different levels of sales or production. For example, a company might pay a smaller percentage on initial sales and a higher percentage as sales increase beyond certain points. This system encourages higher sales by adjusting payments, making it important for investors to understand how revenue sharing may vary as a product or project grows.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN)

Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Visara, Inc. (“Visara”), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. ("NovaBridge") (NASDAQ: NBP), today announced that it has entered into an asset purchase option agreement (the “Option Agreement”) with YOLO Immune (“YOLO”). The Option Agreement provides Visara with an exclusive option to acquire worldwide rights to the YOL104 Program and develop and commercialize YOL104-2 for ocular surface squamous neoplasia (OSSN). YOL104-2 is a trivalent interferon alpha (IFN-α) peptibody currently under investigation for the treatment of OSSN.

“YOL104-2 represents an attractive potential addition to Visara’s pipeline and aligns well with our strategy to build a differentiated ophthalmology portfolio,” said Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Visara. “Through this agreement, we have secured the opportunity to potentially expand our development efforts into an additional area of significant unmet need where there is currently no FDA approved therapy.”

“This transaction demonstrates the NovaBridge approach to disciplined portfolio building: identifying differentiated innovation, pairing it with focused operating expertise and advancing opportunities through the structure best suited to each asset,” said Srishti Gupta, M.D., M.P.P., Chief Executive Officer of NovaBridge. “By securing an exclusive option to acquire YOL104-2, Visara gains the opportunity to further evaluate a differentiated program in ocular surface disease while maintaining flexibility in capital allocation and portfolio development.”

Under the terms of the Option Agreement, Visara will make an upfront payment in exchange for an exclusive option to acquire worldwide title and ownership of the YOL104 Program. If Visara exercises the option and completes the acquisition, YOLO would receive an exercise payment and would be eligible for development, regulatory and commercial milestone payments, as well as tiered royalties on net sales. Additional financial terms were not disclosed.

About YOL104-2
YOL-104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic for the treatment of ocular surface squamous neoplasia (OSSN).

About Ocular Surface Squamous Neoplasia (OSSN)
Ocular Surface Squamous Neoplasia (OSSN) is diagnosis that includes a wide range of cancerous and precancerous growths on the surface of the cornea and conjunctiva. It is linked to sun exposure, HPV infection and a weakened immune system, and it is the most common non-pigmented tumor of the ocular surface.

About Visara
Visara is a clinical stage biotechnology company dedicated to developing next-generation biologic therapies for ophthalmic diseases affecting both the front and back of the eye. From the cornea to the retina, Visara pursues the full spectrum of ocular disease as vision is irreplaceable, and the unmet need is profound. Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP). Its pipeline includes VIS-101, a tetravalent VEGF-A × ANG-2 peptibody being developed for neovascular retinal diseases, and VIS-102, a next-generation modified recombinant human nerve growth factor therapy being developed for neurotrophic keratitis.

About NovaBridge Biosciences
NovaBridge Biosciences ("NovaBridge") (NASDAQ: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing and partnering strategy best suited to each program.

NovaBridge's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB bispecific antibody being developed for the potential treatment of gastrointestinal malignancies, and Visara, its majority-owned ophthalmology subsidiary. Through Visara, NovaBridge is building a diversified ophthalmology franchise designed to address unmet needs across diseases of the front and back of the eye.

NovaBridge's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing novel therapies to patients through the path best suited to each opportunity.

For more information, please visit www.novabridge.com and follow us on LinkedIn.

Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “believes,” “designed to,” “anticipates,” “future,” “intends,” “plans,” “potential,” “estimates,” “confident,” and similar terms or the negative thereof. NovaBridge and Visara may also make written or oral forward-looking statements in NovaBridge’s periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NovaBridge’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the potential exercise of the option to acquire and development of YOL104-2; the potential achievement of development, regulatory and commercial milestones under the Option Agreement; expected milestone and royalty payments under the Option Agreement; the potential benefits of Visara’s product candidates, including VIS-101 and VIS-102; and the strategy, clinical development, plans, timing, results, safety and efficacy of Visara’s drug candidates, including VIS-101 and VIS-102. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: NovaBridge’s or Visara’s ability to demonstrate the safety and efficacy of their drug candidates; the clinical results for their drug candidates, which may or may not support further development or New Drug Application/Biologics License Application approval or eligibility for accelerated approval pathway or receipt of accelerated approval; the content and timing of decisions made by the relevant regulatory authorities, including the FDA, regarding regulatory approval of NovaBridge’s or Visara’s drug candidates; NovaBridge’s or Visara’s ability to achieve commercial success for their drug candidates, if approved; NovaBridge’s or Visara’s ability to obtain and maintain protection of intellectual property for their technology and drugs; NovaBridge’s or Visara’s reliance on third parties to conduct drug development, manufacturing and other services; NovaBridge’s or Visara’s limited operating history and their ability to obtain additional funding for operations and to complete the development and commercialization of their drug candidates; the impact of macroeconomic conditions, including inflation, tariffs, volatile interest rates, regulatory uncertainty, potential government shutdowns, volatility in the capital markets, and regional and other global events, including ongoing armed conflicts in different regions of the world; and those risks more fully discussed in the “Risk Factors” section in NovaBridge’s annual report on Form 20-F filed with the SEC on April 7, 2026, and amended on June 16, 2026, as well as the discussions of potential risks, uncertainties, and other important factors in NovaBridge’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to NovaBridge. NovaBridge undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

NovaBridge Investor & Media Contacts

Investors:
Bill Begien, SVP, Investor Relations
+1-240-745-6330
bill.begien@novabridge.com
IR@novabridge.com

Media Inquiries:
Eric Van Zanten, VP, Communications
+1-610-529-6219
eric.vanzanten@novabridge.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What rights does NovaBridge subsidiary Visara’s YOL104 agreement cover?

Visara holds an exclusive option to acquire worldwide title and ownership of the YOL104 Program from YOLO Immune. The agreement provides an opportunity to develop and commercialize YOL104-2 for ocular surface squamous neoplasia; it is not a completed acquisition.

What payments would Visara make under the YOL104 option agreement?

Visara will make an upfront payment for the option. If Visara exercises it and completes the acquisition, YOLO would receive an exercise payment and become eligible for development, regulatory and commercial milestones, as well as tiered royalties on net sales. Financial amounts were not disclosed.